anti-IL-7Ralpha antibody therapy (Pfizer)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-IL-7Ralpha antibody therapy (Pfizer)

Drug Alias Nameanti-interleukin 7 receptor alpha antibody therapy (Pfizer)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionInterleukin-7 receptors antagonists

TargetsInterleukin-7 receptors

Therapy Area/IndicationsInflammationAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsInflammationAutoimmune Diseases

ATC CodeN/A